Drug Release and Targeting: The Versatility of Polymethacrylate Nanoparticles for Peroral Administration Revealed by Using an Optimized in Vitro-Toolbox

Pharmaceutical Research

Volumn 32, Issue 12, 2015, Pages 3986-3998

  Beyer, Susanne ^a   Moosmann, Aline ^b   Kahnt, Astrid S ^a   Ulshöfer, Thomas ^c   Parnham, Michael J ^c   Ferreirós, Nerea ^d   Wagner, Sylvia ^b   Wacker, Matthias G ^a  

^a GOETHE UNIVERSITY   (Germany)

^b FRAUNHOFER INSTITUTE FOR BIOMEDICAL ENGINEERING   (Germany)

^c FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

biorelevant release; Eudragit RS 100; nanoparticles; peroral drug delivery; Ussing chamber

Indexed keywords

ANTIINFLAMMATORY AGENT; EUDRAGIT RS; NANOPARTICLE; POLYMETHACRYLIC ACID; TMP 001; UNCLASSIFIED DRUG; CYCLOOXYGENASE 2 INHIBITOR; DRUG CARRIER; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; POLYMETHACRYLIC ACID DERIVATIVE;

ARTICLE; CACO 2 CELL LINE; CANCER CELL; CELL ADHESION; CELL INTERACTION; CELL SUSPENSION; CELL VIABILITY; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; ELECTRON MICROSCOPY; ENANTIOMER; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; NANOENCAPSULATION; PARTICLE SIZE; PERMEABILITY; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; SURFACE CHARGE; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; WST-1 ASSAY; ZETA POTENTIAL; CHEMISTRY; DRUG DELIVERY SYSTEM; ORAL DRUG ADMINISTRATION; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; CACO-2 CELLS; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; HUMANS; NANOPARTICLES; PARTICLE SIZE; POLYMETHACRYLIC ACIDS;

EID: 84946472519     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1759-2     Document Type: Article

References (49)

1. Gaumet M, Gurny R, Delie F. Interaction of biodegradable nanoparticles with intestinal cells: the effect of surface hydrophilicity. Int J Pharm. 2010;390(1):45-52.
2. Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008;105(33):11613-8.
3. Kreuter J. Peroral administration of nanoparticles. Adv Drug Deliv Rev. 1991;7(1):71-86.
4. Niebel W, Walkenbach K, Beduneau A, Pellequer Y, Lamprecht A. Nanoparticle-based clodronate delivery mitigates murine experimental colitis. J Control Release. 2012;160(3):659-65.
5. Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle technologies for oral drug delivery. Clin Gastroenterol Hepatol. 2014;12(10):1605-10.
6. Lamprecht A, Schafer U, Lehr CM. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001;18(6):788-93.
7. Rabiskova M, Bautzova T, Gajdziok J, Dvorackova K, Lamprecht A, Pellequer Y, et al. Coated chitosan pellets containing rutin intended for the treatment of inflammatory bowel disease: in vitro characteristics and in vivo evaluation. Int J Pharm. 2012;422(1-2):151-9.
8. Lai SK, Wang Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158-71.
9. Plapied L, Vandermeulen G, Vroman B, Preat V, des Rieux A. Bioadhesive nanoparticles of fungal chitosan for oral DNA delivery. Int J Pharm. 2010;398(1-2):210-8.
10. Tang BC, Dawson M, Lai SK, Wang YY, Suk JS, Yang M, et al. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci U S A. 2009;106(46):19268-73.
11. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64(6):557-70.
12. Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev. 2009;61(2):75-85.
13. Lautenschläger C, Schmidt C, Fischer D, Stallmach A. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev. 2014;71:58-76.
14. Rajapaksa TE, Stover-Hamer M, Fernandez X, Eckelhoefer HA, Lo DD. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Control Release. 2010;142(2):196-205.
15. Schmidt C, Lautenschlaeger C, Collnot EM, Schumann M, Bojarski C, Schulzke JD, et al. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients. J Control Release. 2013;165(2):139-45.
16. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res. 1997;14(11):1568-73.
17. Lehr C-M, Bouwstra JA, Tukker JJ, Junginger HE. Intestinal transit of bioadhesive microspheres in an in situ loop in the rat - a comparative study with copolymers and blends based on poly(acrylic acid). J Control Release. 1990;13(1):51-62.
18. Wacker M. Nanocarriers for intravenous injection-the long hard road to the market. Int J Pharm. 2013;457(1):50-62.
19. Agüeros M, Ruiz-Gatón L, Vauthier C, Bouchemal K, Espuelas S, Ponchel G, et al. Combined hydroxypropyl-β-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci. 2009;38(4):405-13.
20. Beyer S, Xie L, Grafe S, Vogel V, Dietrich K, Wiehe A, et al. Bridging laboratory and large scale production: preparation and in vitro-evaluation of photosensitizer-loaded nanocarrier devices for targeted drug delivery. Pharm Res. 2015;32:1714-26.
21. Dressman JB, Berardi RR, Elta GH, Gray TM, Montgomery PA, Lau HS, et al. Absorption of flurbiprofen in the fed and fasted states. Pharm Res. 1992;9(7):901-7.
22. Moulari B, Beduneau A, Pellequer Y, Lamprecht A. Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis. J Control Release. 2014;188:9-17.
23. Lee SH. Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Intest Res. 2015;13(1):11-8.
24. Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res. 1998;150(5 Suppl):146-56.
25. Crcarevska MS, Dodov MG, Goracinova K. Chitosan coated Ca-alginate microparticles loaded with budesonide for delivery to the inflamed colonic mucosa. Eur J Pharm Biopharm. 2008;68(3):565-78.
26. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1-2):1-20.
27. Ali H, Weigmann B, Neurath MF, Collnot EM, Windbergs M, Lehr CM. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J Control Release. 2014;183:167-77.
28. des Rieux A, Ragnarsson EG, Gullberg E, Preat V, Schneider YJ, Artursson P. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur J Pharm Sci. 2005;25(4-5):455-65.
29. Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci. 2000;11(2):S73-80.
30. Lobenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000;50(1):3-12.
31. Akhlaq M, Khan GM, Wahab A, Khan A, Hussain A, Nawaz A, et al. A simple high-performance liquid chromatographic practical approach for determination of flurbiprofen. J Adv Pharm Technol Res. 2011;2(3):151-5.
32. Ronzani C, Safar R, Diab R, Chevrier J, Paoli J, Abdel-Wahhab MA, et al. Viability and gene expression responses to polymeric nanoparticles in human and rat cells. Cell Biol Toxicol. 2014;30(3):137-46.
33. Safar R, Ronzani C, Diab R, Chevrier J, Bensoussan D, Grandemange S, et al. Human monocyte response to S-nitrosoglutathione-loaded nanoparticles: uptake, viability, and transcriptome. Mol Pharm. 2015;12(2):554-61.
34. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release. 2009;137(1):78-86.
35. Porsch B, Hillang I, Karlsson A, Sundelof LO. Ion-exclusion controlled size-exclusion chromatography of methacrylic acid-methyl methacrylate copolymers. J Chromatogr A. 2000;872(1-2):91-9.
36. des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116(1):1-27.
37. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm. 2000;50(1):147-60.
38. Castelli F, Messina C, Sarpietro MG, Pignatello R, Puglisi G. Flurbiprofen release from Eudragit RS and RL aqueous nanosuspensions: a kinetic study by DSC and dialysis experiments. AAPS PharmSciTech. 2002;3(2).
39. Narisawa S, Nagata M, Hirakawa Y, Kobayashi M, Yoshino H. An organic acid-induced sigmoidal release system for oral controlled-release preparations. 2. Permeability enhancement of Eudragit RS coating led by the physicochemical interactions with organic acid. J Pharm Sci. 1996;85(2):184-8.
40. Donbrow M, Hoffman A, Benita S. Gradation of microcapsule wall porosity by deposition of polymer mixtures (Eudragit RL and Eudragit RS). Phase separation of polymer mixtures and effects of external media and conditions on release. J Microencapsul. 1995;12(3):273-85.
41. Faisant N, Siepmann J, Benoit JP. PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur J Pharm Sci. 2002;15(4):355-66.
42. Mauludin R, Muller RH, Keck CM. Development of an oral rutin nanocrystal formulation. Int J Pharm. 2009;370(1-2):202-9.
43. Onishi H. Pharmacokinetic evaluation of chitosan-succinyl-prednisolone conjugate microparticles as a colonic delivery system: comparison with enteric-coated conjugate microparticles. Health. 2014;6(11):1286-95.
44. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv Drug Deliv Rev. 2001;52(2):139-44.
45. Navabi N, McGuckin MA, Linden SK. Gastrointestinal cell lines form polarized epithelia with an adherent mucus layer when cultured in semi-wet interfaces with mechanical stimulation. PLoS One. 2013;8(7).
46. Navabi N, McGuckin MA, Lindén SK. Gastrointestinal cell lines form polarized epithelia with an adherent mucus layer when cultured in semi-wet interfaces with mechanical stimulation. PLoS ONE. 2013;8(7), e68761.
47. McCool DJ, Marcon MA, Forstner JF, Forstner GG. The T84 human colonic adenocarcinoma cell line produces mucin in culture and releases it in response to various secretagogues. Biochem J. 1990;267(2):491-500.
48. Beduneau A, Tempesta C, Fimbel S, Pellequer Y, Jannin V, Demarne F, et al. A tunable Caco-2/HT29-MTX co-culture model mimicking variable permeabilities of the human intestine obtained by an original seeding procedure. Eur J Pharm Biopharm. 2014;87(2):290-8.
49. Junemann D, Dressman J. Analytical methods for dissolution testing of nanosized drugs. J Pharm Pharmacol. 2012;64(7):931-43.